Central neural mechanisms of cancer cachexia

被引:5
作者
Yule, Michael S. [1 ,2 ]
Brown, Leo R. [3 ]
Skipworth, Richard J. E. [3 ]
Laird, Barry J. A. [1 ,2 ]
机构
[1] St Columbas Hosp, Edinburgh, Scotland
[2] Univ Edinburgh, Edinburgh Canc Res Ctr, Edinburgh, Scotland
[3] Univ Edinburgh, Royal Infirm Edinburgh, Clin Surg, Edinburgh, Scotland
关键词
cachexia; cancer; central; mechanisms; neural; ANOREXIA; RECEPTOR; INFLAMMATION; BEHAVIOR; NUCLEUS; GDF15;
D O I
10.1097/SPC.0000000000000707
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose of reviewCachexia is a devasting syndrome which impacts a large number of patients with cancer. This review aims to provide a comprehensive overview of the central mechanisms of cancer cachexia. In particular, it focuses on the role of the central nervous system (CNS), the melanocortin system, circulating hormones and molecules which are produced by and act on the CNS and the psychological symptoms of cancer cachexia.Recent findingsA growing body of evidence suggests that a central mechanism of action underpins this multi-system disorder. Recent research has focused on the role of neuroinflammation that drives the sickness behaviour seen in cancer cachexia, with emphasis on the role of the hypothalamus. Melanocortin receptor antagonists are showing promise in preclinical studies. There are also new pharmacological developments to overcome the short half-life of ghrelin. GDF-15 has been identified as a core target and trials of compounds that interfere with its signalling or its central receptor are underway.SummaryUnderstanding the central mechanisms of cancer cachexia is pivotal for enhancing treatment outcomes in patients. While emerging pharmacological interventions targeting these pathways have shown promise, further research is essential.
引用
收藏
页码:138 / 144
页数:7
相关论文
共 50 条
[31]   Cellular mechanisms promoting cachexia and how they are opposed by sirtuins [J].
Samant, Sadhana A. ;
Pillai, Vinodkumar B. ;
Gupta, Mahesh P. .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2019, 97 (04) :235-245
[32]   CANCER CACHEXIA [J].
TISDALE, MJ .
ANTI-CANCER DRUGS, 1993, 4 (02) :115-125
[33]   Cachexia and cancer [J].
Torosian, MH .
CANCER JOURNAL - FRANCE, 1995, 8 (06) :299-303
[34]   Cancer cachexia [J].
Barber, MD ;
Ross, JA ;
Fearon, KCH .
SURGICAL ONCOLOGY-OXFORD, 1999, 8 (03) :133-141
[35]   Cancer cachexia [J].
Fearon, KCH ;
Moses, AGW .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 85 (01) :73-81
[36]   Immunoregulation in cancer-associated cachexia [J].
Wu, Qi ;
Li, Zhou ;
Li, Bei ;
Liu, Yu-e ;
Wang, Ping .
JOURNAL OF ADVANCED RESEARCH, 2024, 58 :45-62
[37]   Cancer cachexia: biomarkers and the influence of age [J].
Geppert, Julia ;
Rohm, Maria .
MOLECULAR ONCOLOGY, 2024, 18 (09) :2070-2086
[38]   Tocilizumab in combination with corticosteroids: potential for managing cancer cachexia with systemic hyperinflammation [J].
Chen, Ping ;
Wang, Dingyi ;
Zhan, Zhouwei ;
Chen, Ling ;
Chen, Yu .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[39]   New strategies to overcome cancer cachexia: from molecular mechanisms to the 'Parallel Pathway' [J].
Muscaritoli, Maurizio ;
Costelli, Paola ;
Aversa, Zaira ;
Bonetto, Andrea ;
Baccino, Francesco Maria ;
Rossi Fanelli, Filippo .
ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION, 2008, 17 :387-390
[40]   Molecular Mechanisms and its Clinical Impact in Cancer Cachexia [J].
Bachmann, J. ;
Friess, H. ;
Martignoni, M. E. .
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2008, 46 (12) :1384-1392